You are here: Industry Insights > Kyowa Kirin

News List

EU approval for self-administered Crysvita pharmatimes
July 21, 2021
Kyowa Kirin has received approval in the EU for the self-administration option of its X-linked hypophosphataemia (XLH) treatment Crysvita.
NICE to reassess Kyowa Kirin’s Poteligeo pharmatimes
June 16, 2021
The National Institute for Health and Care Excellence (NICE) will reassess Kyowa Kirin’s rare blood cancer treatment Poteligeo after upholding an appeal launched by the companies and various charities.
Kyowa Kirin: New Data Analysis Shows Link between Blood Involvement and Response to Treatment in Cutaneous T-cell Lymphoma (CTCL) Patients firstwordpharma
June 11, 2021
Kyowa Kirin today announced a new analysis of data showing statistically significant improvements in quality of life in cutaneous T-cell lymphoma (CTCL) patients treated with mogamulizumab with blood involvement, compared to vorinostat.
Amgen and Kyowa Kirin to Jointly Develop and Commercialize KHK4083, a Phase 3-Ready, Potential First-In-Class Treatment for Atopic Dermatitis prnasia
June 02, 2021
Amgen and Kyowa Kirin Co., Ltd. announced an agreement to jointly develop and commercialize KHK4083, which is Kyowa Kirin's potential first-in-class, Phase 3-ready anti-OX40 fully human monoclonal antibody in development for the treatment of ...
Amgen and Kyowa Kirin agree to jointly develop eczema med pharmatimes
June 02, 2021
Amgen and Kyowa Kirin have signed an agreement to jointly develop and commercialise KHK4083, a monoclonal antibody (mAb) in development for the treatment of atopic dermatitis – the most common form of eczema.
Positive CHMP opinion for self-administered Crysvita pharmatimes
May 11, 2021
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended Kyowa Kirin’s Crysvita for a new self-administration option to treat the rare metabolic bone disease X-linked hypophosphataemia (XLH).
NICE rejects Kyowa Kirin’s rare blood cancer drug Poteligeo for NHS use pharmaceutical-technology
March 05, 2021
The UK’s drug pricing regulator the National Institute for Health and Care Excellence (NICE) has decided not to recommend Kyowa Kirin’s Poteligeo (mogamulizumab) for routine use in the National Health Service (NHS) in England and Wales.
A Novel Drug-Device Combination Product Using Terumo's Automated Injection Device Completes Clinical Study in Japan prnasia
February 08, 2021
Terumo Corporation today announced the completion of a clinical study in Japan for a product using Terumo's automated injection device developed in collaboration with Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin).
NICE rejects NHS funding for Kyowa Kirin's Poteligeo pharmatimes
July 31, 2020
NICE is not recommending NHS funding for Kyowa Kirin's Poteligeo (mogamulizumab) as a treatment for mycosis fungoides or Sézary syndrome for adults who have had at least one previous systemic treatment.
CHMP backs expanding scope of Kyowa Kirin's Crysvita pharmatimes
July 28, 2020
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended expanding approval of Kyowa Kirin's Crysvita (burosumab) to include older adolescents and adults living with X-linked hypophosphataemia (XLH).

Previous page 1 2 Next page